Antithrombotic Treatment Patterns in Patients with Atrial Fibrillation in Italy Pre- and Post-DOACs: the REPAIR Study

Overview

Journal Future Cardiol

Specialty Cardiology & Vascular Diseases

Date 2019 Jan 22

PMID 30663889

Citations 3

Authors

Luca D Esposti

Jean-Baptiste Briere

Kevin Bowrin

Sangiorgi Diego

Valentina Perrone

Giuseppe Di Pasquale

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate antithrombotic treatment patterns in patients in Italy with nonvalvular atrial fibrillation (NVAF) before and after direct oral anticoagulants (DOACs) were approved.

Methods: This analysis included patients with a discharge diagnosis of NVAF in 2010 and 2014, which constituted the pre- and post-DOACs populations, respectively.

Results: Approximately 90% of patients were eligible for oral anticoagulant (OAC) therapy. Overall use of OACs increased from 38% in 2010 to 45% in 2014; use of antiplatelet therapy decreased from 36 to 25%. Approximately 14% of eligible patients remained untreated.

Conclusion: Although an improvement in OAC prescription was observed post-DOACs launch, treatment patterns in Italy suggest that a proportion of patients with NVAF are still undertreated or do not receive appropriate therapy.

Citing Articles

Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation.

Atwater B, Guo J, Keshishian A, Delinger R, Russ C, Rosenblatt L J Thromb Thrombolysis. 2023; 57(1):1-10.

PMID: 37530955 PMC: 10830709. DOI: 10.1007/s11239-023-02838-2.

Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation.

Abrignani M, Lombardo A, Braschi A, Renda N, Abrignani V, Lombardo R World J Cardiol. 2022; 14(11):576-598.

PMID: 36483763 PMC: 9724000. DOI: 10.4330/wjc.v14.i11.576.

Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation.

Mostaza J, Suarez C, Cepeda J, Manzano L, Sanchez D BMC Cardiovasc Disord. 2021; 21(1):384.

PMID: 34372782 PMC: 8351138. DOI: 10.1186/s12872-021-02019-0.

References

Gattellari M, Worthington J, Zwar N, Middleton S . Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke. 2007; 39(1):227-30. DOI: 10.1161/STROKEAHA.107.495036. View

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

Agarwal S, Bennett D, Smith D . Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs. 2010; 10(1):37-48. DOI: 10.2165/11318870-000000000-00000. View

Camm A, Kirchhof P, Lip G, Schotten U, Savelieva I, Ernst S . Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19):2369-429. DOI: 10.1093/eurheartj/ehq278. View

Zhou A, Winkler A, Emamifar A, Gartland B, Duncan A, Antun A . Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis?. Chest. 2012; 142(5):1175-1178. DOI: 10.1378/chest.11-2926. View

Camm A, Lip G, De Caterina R, Savelieva I, Atar D, Hohnloser S . 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21):2719-47. DOI: 10.1093/eurheartj/ehs253. View

Zoni-Berisso M, Filippi A, Landolina M, Brignoli O, DAmbrosio G, Maglia G . Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study). Am J Cardiol. 2013; 111(5):705-11. DOI: 10.1016/j.amjcard.2012.11.026. View

Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey J, Schilling R . Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2013; 16(1):6-14. PMC: 3864758. DOI: 10.1093/europace/eut263. View

De Caterina R, Ammentorp B, Darius H, Le Heuzey J, Renda G, Schilling R . Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart. 2014; 100(20):1625-35. DOI: 10.1136/heartjnl-2014-305486. View

10.

Farner S, Malkani A, Lau E, Day J, Ochoa J, Ong K . Outcomes and cost of care for patients with distal radius fractures. Orthopedics. 2014; 37(10):e866-78. DOI: 10.3928/01477447-20140924-52. View

11.

Wehbe R, Yadlapati A . Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future. Tex Heart Inst J. 2016; 43(4):287-90. PMC: 4979382. DOI: 10.14503/THIJ-16-5785. View

12.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893-2962. DOI: 10.1093/eurheartj/ehw210. View

13.

Camm A, Accetta G, Ambrosio G, Atar D, Bassand J, Berge E . Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2016; 103(4):307-314. PMC: 5293840. DOI: 10.1136/heartjnl-2016-309832. View

14.

Basaran O, Beton O, Dogan V, Tekinalp M, Aykan A, Kalaycioglu E . ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). Anatol J Cardiol. 2016; 16(10):734-741. PMC: 5324932. DOI: 10.14744/AnatolJCardiol.2016.6752. View

15.

Perrone V, Saragoni S, Buda S, Broccoli A, Degli Esposti L . Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars. Biologics. 2016; 10:157-165. PMC: 5137929. DOI: 10.2147/BTT.S114625. View

16.

Renda G, Patti G, Sangiuolo R, Attena E, Malpezzi M, De Caterina R . [Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry]. G Ital Cardiol (Rome). 2016; 17(11):922-931. DOI: 10.1714/2498.26200. View

17.

Huisman M, Rothman K, Paquette M, Teutsch C, Diener H, Dubner S . The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017; 69(7):777-785. DOI: 10.1016/j.jacc.2016.11.061. View

18.

Camm A, Accetta G, Al Mahmeed W, Ambrosio G, Goldhaber S, Haas S . Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 2017; 7(3):e014579. PMC: 5353285. DOI: 10.1136/bmjopen-2016-014579. View

19.

Deambrosis P, Bettiol A, Bolcato J, Pirolo R, Franchin G, Themistoclakis S . Real-practice thromboprophylaxis in atrial fibrillation. Acta Pharm. 2017; 67(2):227-236. DOI: 10.1515/acph-2017-0016. View

20.

Ceornodolea A, Bal R, Severens J . Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries. Stroke Res Treat. 2017; 2017:8593207. PMC: 5467327. DOI: 10.1155/2017/8593207. View